$EYEN
EYENOVIA, INC.

2023 Q4 Form 10-Q Financial Statement

#000141057823002416 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $2.590K $1.198K
YoY Change
Cost Of Revenue $2.590K $1.198K
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin 0.0% 0.0%
Selling, General & Admin $3.402M $2.940M
YoY Change 7.32% -12.33%
% of Gross Profit
Research & Development $4.065M $3.578M
YoY Change 78.16% -7.71%
% of Gross Profit
Depreciation & Amortization $277.5K $320.0K
YoY Change 253.41% 285.54%
% of Gross Profit
Operating Expenses $7.467M $6.520M
YoY Change 38.98% -9.82%
Operating Profit -$7.467M -$6.520M
YoY Change 38.98% -9.82%
Interest Expense -$482.0K $679.2K
YoY Change -43.41% 283.44%
% of Operating Profit
Other Income/Expense, Net -$18.63K -$818.5K
YoY Change -118.54% -1264.74%
Pretax Income -$7.967M -$7.340M
YoY Change 30.11% 0.42%
Income Tax
% Of Pretax Income
Net Earnings -$7.967M -$7.339M
YoY Change 30.11% 0.41%
Net Earnings / Revenue -307611.58% -612582.05%
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$0.16 -$0.18
COMMON SHARES
Basic Shares Outstanding 44.12M 0.000
Diluted Shares Outstanding 40.14M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.85M $20.70M
YoY Change -35.39% 18.98%
Cash & Equivalents $14.80M $20.70M
Short-Term Investments $0.00
Other Short-Term Assets $5.123M $4.880M
YoY Change 82.02% -53.91%
Inventory $109.8K $50.30K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $20.71M $26.53M
YoY Change -25.09% -9.8%
LONG-TERM ASSETS
Property, Plant & Equipment $5.041M $3.531M
YoY Change 289.24% 163.01%
Goodwill
YoY Change
Intangibles $2.123M $2.123M
YoY Change
Long-Term Investments $200.0K
YoY Change -0.07%
Other Assets $908.6K $690.0K
YoY Change 25.1% 6.86%
Total Long-Term Assets $8.073M $8.332M
YoY Change 137.86% 319.06%
TOTAL ASSETS
Total Short-Term Assets $20.71M $26.53M
Total Long-Term Assets $8.073M $8.332M
Total Assets $28.78M $34.87M
YoY Change -7.27% 11.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.753M $1.426M
YoY Change 22.75% 29.06%
Accrued Expenses $2.413M $2.060M
YoY Change -9.98% -19.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $5.329M $3.010M
YoY Change 1427.49%
Total Short-Term Liabilities $9.530M $6.548M
YoY Change 111.21% -40.56%
LONG-TERM LIABILITIES
Long-Term Debt $8.957M $11.10M
YoY Change 6.86%
Other Long-Term Liabilities $1.293M $1.440M
YoY Change 42.42% 2278.59%
Total Long-Term Liabilities $10.25M $12.54M
YoY Change 10.34% 20613.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.530M $6.548M
Total Long-Term Liabilities $10.25M $12.54M
Total Liabilities $19.78M $19.09M
YoY Change 43.32% 72.31%
SHAREHOLDERS EQUITY
Retained Earnings -$145.5M -$137.5M
YoY Change 23.1% 22.68%
Common Stock $4.555K $4.290K
YoY Change 24.22% 20.74%
Preferred Stock
YoY Change
Treasury Stock (at cost) $5.450M $5.221M
YoY Change
Treasury Stock Shares
Shareholders Equity $8.999M $15.78M
YoY Change
Total Liabilities & Shareholders Equity $28.78M $34.87M
YoY Change -7.27% 11.02%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$7.967M -$7.339M
YoY Change 30.11% 0.41%
Depreciation, Depletion And Amortization $277.5K $320.0K
YoY Change 253.41% 285.54%
Cash From Operating Activities -$6.322M -$5.840M
YoY Change 16.97% -14.33%
INVESTING ACTIVITIES
Capital Expenditures $145.2K $580.0K
YoY Change 368.64% -354.35%
Acquisitions
YoY Change
Other Investing Activities -$2.950K -$1.120M
YoY Change -98.95% -1830.8%
Cash From Investing Activities -$145.2K -$1.710M
YoY Change -53.42% 947.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 614.3K 10.78M
YoY Change -81.42% 275.3%
NET CHANGE
Cash From Operating Activities -6.322M -5.840M
Cash From Investing Activities -145.2K -1.710M
Cash From Financing Activities 614.3K 10.78M
Net Change In Cash -5.853M 3.230M
YoY Change 142.86% -178.63%
FREE CASH FLOW
Cash From Operating Activities -$6.322M -$5.840M
Capital Expenditures $145.2K $580.0K
Free Cash Flow -$6.467M -$6.420M
YoY Change 18.98% -2.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Central Index Key
EntityCentralIndexKey
0001682639
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42898246
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36668980
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38365
dei Entity Registrant Name
EntityRegistrantName
EYENOVIA, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1178401
dei Entity Address Address Line1
EntityAddressAddressLine1
295 Madison Avenue, Suite 2400
dei Entity Address City Or Town
EntityAddressCityOrTown
NEW YORK
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
393-6684
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
EYEN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44122225
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20702212
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22863520
CY2023Q3 us-gaap Inventory Net
InventoryNet
50296
CY2023Q3 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
3622687
CY2022Q4 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
2284931
CY2023Q3 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
397014
CY2022Q4 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
1183786
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
119550
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1760824
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1190719
CY2023Q3 us-gaap Assets Current
AssetsCurrent
26533033
CY2022Q4 us-gaap Assets Current
AssetsCurrent
27642506
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3531365
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1295115
CY2023Q3 eyen Security Deposits
SecurityDeposits
198674
CY2022Q4 eyen Security Deposits
SecurityDeposits
80874
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2122945
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1792667
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1291592
CY2023Q3 eyen Equipment Deposits
EquipmentDeposits
686753
CY2022Q4 eyen Equipment Deposits
EquipmentDeposits
726326
CY2023Q3 us-gaap Assets
Assets
34865437
CY2022Q4 us-gaap Assets
Assets
31036413
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1426028
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1428283
CY2023Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1375832
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1747191
CY2023Q3 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
295703
CY2022Q4 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
503076
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
444616
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
484882
CY2023Q3 eyen Notes Payable Unamortized Discount Current
NotesPayableUnamortizedDiscountCurrent
327217
CY2022Q4 eyen Notes Payable Unamortized Discount Current
NotesPayableUnamortizedDiscountCurrent
33885
CY2023Q3 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
3006116
CY2022Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
174448
CY2023Q3 eyen Convertible Notes Payable Unamortized Discount Current
ConvertibleNotesPayableUnamortizedDiscountCurrent
0
CY2022Q4 eyen Convertible Notes Payable Unamortized Discount Current
ConvertibleNotesPayableUnamortizedDiscountCurrent
33885
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
174448
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6548295
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4512328
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1441081
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
907644
CY2023Q3 eyen Notes Payable Unamortized Discount Noncurrent
NotesPayableUnamortizedDiscountNoncurrent
754919
CY2022Q4 eyen Notes Payable Unamortized Discount Noncurrent
NotesPayableUnamortizedDiscountNoncurrent
813229
CY2023Q3 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
6549248
CY2022Q4 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
4190938
CY2023Q3 eyen Convertible Notes Payable Unamortized Discount Noncurrent
ConvertibleNotesPayableUnamortizedDiscountNoncurrent
452920
CY2022Q4 eyen Convertible Notes Payable Unamortized Discount Noncurrent
ConvertibleNotesPayableUnamortizedDiscountNoncurrent
813229
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4547080
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4190938
CY2023Q3 us-gaap Liabilities
Liabilities
19085704
CY2022Q4 us-gaap Liabilities
Liabilities
13801848
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42898246
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36668980
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
4290
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3667
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
153299865
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
135461361
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137524422
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118230463
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
15779733
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17234565
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34865437
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31036413
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1198
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1198
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
1198
us-gaap Cost Of Revenue
CostOfRevenue
1198
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3578113
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3876876
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8911124
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11176326
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2942073
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3353352
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9028768
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10362907
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
6520186
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7230228
us-gaap Operating Expenses
OperatingExpenses
17939892
us-gaap Operating Expenses
OperatingExpenses
21539233
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6520186
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7230228
us-gaap Operating Income Loss
OperatingIncomeLoss
-17939892
us-gaap Operating Income Loss
OperatingIncomeLoss
-21539233
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-348226
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
70277
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-157783
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
96580
CY2023Q3 us-gaap Interest Expense
InterestExpense
679222
CY2022Q3 us-gaap Interest Expense
InterestExpense
177138
us-gaap Interest Expense
InterestExpense
1691228
us-gaap Interest Expense
InterestExpense
475811
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
208901
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
28093
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
494944
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
30703
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-818547
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-78768
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1354067
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-348528
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7338733
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7308996
us-gaap Net Income Loss
NetIncomeLoss
-19293959
us-gaap Net Income Loss
NetIncomeLoss
-21887761
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40139697
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40139697
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34631774
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34631774
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38563074
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38563074
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32778551
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32778551
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17234565
CY2023Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
3499592
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
819064
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5739366
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15813855
CY2023Q2 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
403120
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27200
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
493632
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6215860
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10521947
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10886114
CY2023Q3 eyen Stock Issued During Period Value Licensing Agreements
StockIssuedDuringPeriodValueLicensingAgreements
1000000
CY2023Q3 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
97436
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1738700
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1738700
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
612969
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7338733
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
15779733
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20466615
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14897908
CY2022Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
860365
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
908987
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7339665
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
29794210
CY2022Q2 eyen Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
18701
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1036926
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7239100
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23610737
CY2022Q3 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
3098694
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
928733
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7308996
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
20329168
us-gaap Net Income Loss
NetIncomeLoss
-19293959
us-gaap Net Income Loss
NetIncomeLoss
-21887761
us-gaap Share Based Compensation
ShareBasedCompensation
1925665
us-gaap Share Based Compensation
ShareBasedCompensation
2874646
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
505684
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
228898
eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
497654
eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
78645
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
209040
us-gaap Inventory Write Down
InventoryWriteDown
12218
eyen Provision For Returned Deferred Clinical Supplies
ProvisionForReturnedDeferredClinicalSupplies
400000
eyen Non Cash Rent Expense
NonCashRentExpense
403362
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39035
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
66250
eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
-786772
eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
-995635
eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
1637756
eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
1871096
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
62514
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
1750
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-67614
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2255
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-509145
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-371359
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-275609
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-307373
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
539084
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-411266
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
50905
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17514342
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19700622
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2702361
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
509370
eyen Vendor Deposits For Property Plant And Equipment
VendorDepositsForPropertyPlantAndEquipment
53589
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1122945
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3825306
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-562959
eyen Proceeds From Sale Of Common Stock And Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering
11977468
eyen Proceeds From Sale Of Common Stock And Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering
14981299
eyen Payments For Repurchase Of Public Offering
PaymentsForRepurchaseOfPublicOffering
1091354
eyen Payments For Repurchase Of Public Offering
PaymentsForRepurchaseOfPublicOffering
83391
eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
4123864
eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
4081504
eyen Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
123716
eyen Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
122445
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27200
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18701
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
125982
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
609140
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
675332
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19178340
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18200336
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2161308
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2063245
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22863520
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27336850
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20702212
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25273605
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20702212
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17398605
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
7875000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20702212
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25273605
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
1194132
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
315550
eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
609140
eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
675332
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
904437
us-gaap Escrow Deposit Disbursements Related To Property Acquisition1
EscrowDepositDisbursementsRelatedToPropertyAcquisition1
39573
eyen Original Issue Discount On Notes Payable
OriginalIssueDiscountOnNotesPayable
212500
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1738700
us-gaap Stock Issued1
StockIssued1
1000000
eyen Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
2
eyen Issuance Of Common Stock Related To Vested Restricted Stock Units
IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits
4
eyen Issuance Of Common Stock Related To Vested Restricted Stock Units
IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits
9
eyen Proceeds Of Stock Issued During Period Gross
ProceedsOfStockIssuedDuringPeriodGross
14981299
eyen Proceeds Of Stock Issued During Period Gross
ProceedsOfStockIssuedDuringPeriodGross
11977468
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
305349
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
445269
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
106134
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20700000
us-gaap Net Income Loss
NetIncomeLoss
-19300000
us-gaap Net Income Loss
NetIncomeLoss
-21900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17500000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19700000
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
5221319
CY2023Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
15056184
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
22613520
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7338733
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7308996
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19293959
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21887761
CY2023Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
39107338
CY2022Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
34564366
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
38192414
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
32260723
CY2023Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
926225
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
67408
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
65311
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
72559
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40139697
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34631774
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38563074
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32778551
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18559192
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11745332
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
24506
CY2023Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
25790
CY2023Q3 us-gaap Inventory Net
InventoryNet
50296
CY2022Q4 eyen Prepaid Conference Expenses Current
PrepaidConferenceExpensesCurrent
97743
CY2023Q3 eyen Prepaid Professional Fees Current
PrepaidProfessionalFeesCurrent
193750
CY2022Q4 eyen Prepaid Professional Fees Current
PrepaidProfessionalFeesCurrent
0
CY2023Q3 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
500684
CY2022Q4 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
660891
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
375961
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
201082
CY2023Q3 eyen Prepaid Conference Expenses Current
PrepaidConferenceExpensesCurrent
345334
CY2023Q3 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
155767
CY2022Q4 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2521
CY2023Q3 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
110659
CY2022Q4 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
87982
CY2023Q3 eyen Prepaid Patent Expense
PrepaidPatentExpense
59919
CY2022Q4 eyen Prepaid Patent Expense
PrepaidPatentExpense
38796
CY2023Q3 eyen Prepaid Security Deposits
PrepaidSecurityDeposits
18750
CY2022Q4 eyen Prepaid Security Deposits
PrepaidSecurityDeposits
74959
CY2023Q3 us-gaap Other Assets
OtherAssets
0
CY2022Q4 us-gaap Other Assets
OtherAssets
26745
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1760824
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1190719
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4672887
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1930953
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1141522
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
635838
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3531365
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1295115
CY2023Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1048249
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1447643
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
327583
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
299548
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1375832
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1747191
CY2023Q3 eyen Accrued Rework Of Clinical Supply Returns Current
AccruedReworkOfClinicalSupplyReturnsCurrent
100000
CY2022Q4 eyen Accrued Rework Of Clinical Supply Returns Current
AccruedReworkOfClinicalSupplyReturnsCurrent
0
CY2023Q3 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
45000
CY2022Q4 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
35524
CY2023Q3 eyen Credit Card Payable
CreditCardPayable
53751
CY2022Q4 eyen Credit Card Payable
CreditCardPayable
50639
CY2023Q3 eyen Accrued Consulting And Professional Services Current
AccruedConsultingAndProfessionalServicesCurrent
46750
CY2022Q4 eyen Accrued Consulting And Professional Services Current
AccruedConsultingAndProfessionalServicesCurrent
320000
CY2023Q3 eyen Accrued Franchise Tax
AccruedFranchiseTax
39300
CY2022Q4 eyen Accrued Franchise Tax
AccruedFranchiseTax
0
CY2023Q3 eyen Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
0
CY2022Q4 eyen Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
92528
CY2023Q3 eyen Accrued Travel And Entertainment Expenses Current
AccruedTravelAndEntertainmentExpensesCurrent
10033
CY2022Q4 eyen Accrued Travel And Entertainment Expenses Current
AccruedTravelAndEntertainmentExpensesCurrent
0
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
869
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4385
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
295703
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
503076
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
3333333
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
327217
CY2023Q3 eyen Notes Payable Current Net Of Debt Discount Current Current Portion
NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion
3006116
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
416666
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
67770
CY2022Q4 eyen Notes Payable Current Net Of Debt Discount Current Current Portion
NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion
348896
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
12304167
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1207839
CY2023Q3 eyen Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion
NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion
11096328
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
10008334
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1626458
CY2022Q4 eyen Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion
NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion
8381876
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
609140
CY2023Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
126000
us-gaap Operating Lease Payments
OperatingLeasePayments
411266
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
904437
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M10D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
137838
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
660923
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
675400
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
560996
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
214619
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2249776
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
364079
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1885697
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
444616
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1441081
eyen Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
4000000.0
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1464346
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6087845
CY2022Q4 eyen Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
3.37
eyen Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
7091688
eyen Class Of Warrant Or Right Granted Weighted Average Exercise Price
ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice
1.52
eyen Class Of Warrant Or Right New Repriced
ClassOfWarrantOrRightNewRepriced
-4870130
eyen Class Of Warrant Or Right Old Repriced Weighted Average Exercise Price
ClassOfWarrantOrRightOldRepricedWeightedAverageExercisePrice
3.54
eyen Class Of Warrant Or Right Old Repriced
ClassOfWarrantOrRightOldRepriced
4870130
eyen Class Of Warrant Or Right New Repriced Weighted Average Exercise Price
ClassOfWarrantOrRightNewRepricedWeightedAverageExercisePrice
2.23
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13179533
CY2023Q3 eyen Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
1.89
eyen Class Of Warrant Or Right Outstanding Weighted Average Remaining Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife
P4Y2M12D
CY2023Q3 eyen Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
3470694
CY2023Q3 eyen Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
0.95
eyen Class Of Warrant Or Right Exercisable Weighted Average Remaining Life
ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife
P0Y8M12D
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13179533
eyen Class Of Warrant Or Right Exercisable Weighted Average Remaining Life
ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife
P0Y8M12D
CY2023Q3 eyen Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
3470694
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
612969
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
928733
us-gaap Share Based Compensation
ShareBasedCompensation
1925665
us-gaap Share Based Compensation
ShareBasedCompensation
2874646
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
172800
CY2022Q4 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
1.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
86205
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
2.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
150578
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice
1.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
22222
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Forfeited In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice
1.80
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
86205
CY2023Q3 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
2.32
eyen Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Rs Us Undelivered Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber
135745
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested Rs Us Undelivered Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice
2.22
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5218686
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y2M12D
CY2023Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3835305
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2841102
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2019Q2 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2019Q2 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.04
CY2023Q3 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
46636
CY2022Q3 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
39914
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
171800
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
173896
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001410578-23-002416-index-headers.html Edgar Link pending
0001410578-23-002416-index.html Edgar Link pending
0001410578-23-002416.txt Edgar Link pending
0001410578-23-002416-xbrl.zip Edgar Link pending
eyen-20230930.xsd Edgar Link pending
eyen-20230930x10q.htm Edgar Link pending
eyen-20230930xex10d1.htm Edgar Link pending
eyen-20230930xex31d1.htm Edgar Link pending
eyen-20230930xex31d2.htm Edgar Link pending
eyen-20230930xex32d1.htm Edgar Link pending
eyen-20230930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
eyen-20230930_def.xml Edgar Link unprocessable
eyen-20230930_lab.xml Edgar Link unprocessable
eyen-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
eyen-20230930_cal.xml Edgar Link unprocessable
eyen-20230930x10q_htm.xml Edgar Link completed